Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Asia-Pacific Bronchiectasis Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991795
Published Content info 357 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia-Pacific Bronchiectasis Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 357 Pages
Description

Asia-Pacific bronchiectasis market is projected to register a healthy CAGR of 6.5% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation

Asia-Pacific Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of Asia-Pacific bronchiectasis market are:

  • Availability of generic drugs in underdeveloped and developing countries.
  • Rising patient population suffering from bronchiectasis.

Market Players

The key market players for the bronchiectasis market are listed below:

  • Abott
  • HERSILL
  • Inogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Medline Industries, Inc
  • Ache Laboratories Farmaceuticos S.A.
  • Johnson & Johnson, Inc.
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Cipla Inc.
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF ASIA PACIFIC BRONCHIECTASIS MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 DISEASE TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET DRUGS TYPE COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 ASIA PACIFIC BRONCHIECTASIS MARKET: LAWS AND REGULATIONS

6 EPIDEMIOLOGY

7 MARKET OVERVIEW

  • 7.1 DRIVERS
    • 7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
    • 7.1.2 GROWING GERIATRIC POPULATION
    • 7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
    • 7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
    • 7.1.5 GROWING DIAGNOSTIC RATE
  • 7.2 RESTRAINTS
    • 7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
    • 7.2.2 PRODUCT RECALLS
    • 7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
  • 7.3 OPPORTUNITIES
    • 7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE
    • 7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
    • 7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
  • 7.4 CHALLENGES
    • 7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
    • 7.4.2 LACK OF SKILLED PROFESSIONALS
    • 7.4.3 DIAGNOSITIC CHALLENGES

8 IMPACT OF COVID-19

  • 8.1 PRICE IMPACT
  • 8.2 IMPACT ON DEMAND
  • 8.3 IMPACT ON SUPPLY CHAIN
  • 8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 8.5 CONCLUSION

9 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-CF BRONCHIECTASIS
  • 9.3 CF BRONCHIECTASIS

10 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MILD TO MODERATE
  • 10.3 MODERATE TO SEVERE

11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 TREATMENT
    • 11.2.1 ANTIBIOTICS
      • 11.2.1.1 MACROLIDE
        • 11.2.1.1.1 AZITHROMYCIN
        • 11.2.1.1.2 CLARITHROMYCIN
        • 11.2.1.1.3 OTHERS
      • 11.2.1.2 AMOXICILLIN
      • 11.2.1.3 CEPHALOSPORIN
        • 11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
        • 11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
      • 11.2.1.4 AMINOGLYCOSIDE
        • 11.2.1.4.1 GENTAMICIN
        • 11.2.1.4.2 TOBRAMYCIN
      • 11.2.1.5 FLUOROQUINOLONE
      • 11.2.1.6 TETRACYCLINS
      • 11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
      • 11.2.1.8 COMBINATION THERAPY
    • 11.2.2 CORTICOSTEROIDS
      • 11.2.2.1 BUDESONIDE
      • 11.2.2.2 FLUTICASONE
      • 11.2.2.3 MOMETASONE
      • 11.2.2.4 FLUNISOLIDE
      • 11.2.2.5 OTHERS
    • 11.2.3 BRONCHODILATORS
      • 11.2.3.1 LONG-ACTING BRONCHODILATORS
        • 11.2.3.1.1 FORMOTEROL
        • 11.2.3.1.2 TIOTROPIUM
        • 11.2.3.1.3 SALMETEROL
        • 11.2.3.1.4 OTHERS
      • 11.2.3.2 SHORT-ACTING BRONCHODILATORS
        • 11.2.3.2.1 ALBUTEROL
        • 11.2.3.2.2 LEVALBUTEROL
        • 11.2.3.2.3 OTHERS
    • 11.2.4 MUCUS THINNING MEDICINE
      • 11.2.4.1 CARBOCISTEINE
      • 11.2.4.2 BROMHEXINE
      • 11.2.4.3 OTHERS
    • 11.2.5 AIRWAY CLEARANCE DEVICES
      • 11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
      • 11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
      • 11.2.5.3 POSTURAL DRAINAGE
      • 11.2.5.4 OTHERS
    • 11.2.6 OXYGEN THERAPY
      • 11.2.6.1 OXYGEN CONCENTRATORS
      • 11.2.6.2 COMPRESSED GAS OXYGEN
      • 11.2.6.3 LIQUID OXYGEN
    • 11.2.7 SURGERY
      • 11.2.7.1 BRONCHOSCOPY
      • 11.2.7.2 LUNG TRANSPLANT
    • 11.2.8 OTHERS
  • 11.3 DIAGNOSIS
    • 11.3.1 CHEST CT SCAN
    • 11.3.2 SPUTUM TEST
    • 11.3.3 PULMONARY FUNCTION TEST
    • 11.3.4 X-RAY
    • 11.3.5 OTHERS

12 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE

  • 12.1 OVERVIEW
  • 12.2 BRANDED
  • 12.3 GENERICS

13 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION

  • 13.1 OVERVIEW
  • 13.2 INHALATION
  • 13.3 ORAL
    • 13.3.1 TABLETS
    • 13.3.2 CAPSULES
    • 13.3.3 OTHERS
  • 13.4 PARENTERAL
    • 13.4.1 INTRAVENOUS
    • 13.4.2 SUBCUTANEOUS
    • 13.4.3 OTHERS

14 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 CLINICS
  • 14.4 HOME HEALTHCARE
  • 14.5 OTHERS

15 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE PHARMACY
  • 15.5 OTHERS

16 ASIA PACIFIC BRONCHIECTASIS MARKET BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 ASIA-PACIFIC
    • 16.2.1 JAPAN
    • 16.2.2 CHINA
    • 16.2.3 INDIA
    • 16.2.4 AUSTRALIA
    • 16.2.5 SOUTH KOREA
    • 16.2.6 SINGAPORE
    • 16.2.7 MALAYSIA
    • 16.2.8 THAILAND
    • 16.2.9 INDONESIA
    • 16.2.10 PHILIPPINES
    • 16.2.11 VIETNAM
    • 16.2.12 REST OF ASIA-PACIFIC

17 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

18 SWOT

19 COMPANY PROFILES

  • 19.1 ASTRAZENECA
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 PRODUCT PORTFOLIO
    • 19.1.5 RECENT DEVELOPMENTS
  • 19.2 GLAXOSMITHKLINE PLC.
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 PRODUCT PORTFOLIO
    • 19.2.5 RECENT DEVELOPMENTS
  • 19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 COMPANY SHARE ANALYSIS
    • 19.3.4 PRODUCT PORTFOLIO
    • 19.3.5 RECENT DEVELOPMENTS
  • 19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 COMPANY SHARE ANALYSIS
    • 19.4.4 PRODUCT PORTFOLIO
    • 19.4.5 RECENT DEVELOPMENTS
  • 19.5 NOVARTIS AG
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 PRODUCT PORTFOLIO
    • 19.5.4 RECENT DEVELOPMENTS
  • 19.6 ABBOTT
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 REVENUE ANALYSIS
    • 19.6.3 PRODUCT PORTFOLIO
    • 19.6.4 RECENT DEVELOPMENT
  • 19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 PRODUCT PORTFOLIO
    • 19.7.3 RECENT DEVELOPMENTS
  • 19.8 BAYER AG
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 REVENUE ANALYSIS
    • 19.8.3 PRODUCT PORTFOLIO
    • 19.8.4 RECENT DEVELOPMENTS
  • 19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 PRODUCT PORTFOLIO
    • 19.9.4 RECENT DEVELOPMENT
  • 19.10 CIPLA INC.
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 REVENUE ANALYSIS
    • 19.10.3 PRODUCT PORTFOLIO
    • 19.10.4 RECENT DEVELOPMENTS
  • 19.11 COVIS PHARMA
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 PRODUCT PORTFOLIO
    • 19.11.3 RECENT DEVELOPMENT
  • 19.12 DR. REDDY'S LABORATORIES LTD.
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 PRODUCT PORTFOLIO
    • 19.12.4 RECENT DEVELOPMENTS
  • 19.13 ELECTROMED, INC.
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 REVENUE ANALYSIS
    • 19.13.3 PRODUCT PORTFOLIO
    • 19.13.4 RECENT DEVELOPMENTS
  • 19.14 HERSILL
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 PRODUCT PORTFOLIO
    • 19.14.3 RECENT DEVELOPMENTS
  • 19.15 HOME OXYGEN COMPANY
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 PRODUCT PORTFOLIO
    • 19.15.3 RECENT DEVELOPMENT
  • 19.16 HORIZON THERAPEUTICS PLC
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 PRODUCT PORTFOLIO
    • 19.16.4 RECENT DEVELOPMENT
  • 19.17 INOGEN, INC.
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 REVENUE ANALYSIS
    • 19.17.3 PRODUCT PORTFOLIO
    • 19.17.4 RECENT DEVELOPMENTS
  • 19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 PRODUCT PORTFOLIO
    • 19.18.4 RECENT DEVELOPMENT
  • 19.19 MEDLINE INDUSTRIES, INC.
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 PRODUCT PORTFOLIO
    • 19.19.3 RECENT DEVELOPMENTS
  • 19.20 PFIZER INC.
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 REVENUE ANALYSIS
    • 19.20.3 PRODUCT PORTFOLIO
    • 19.20.4 RECENT DEVELOPMENTS
  • 19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 REVENUE ANALYSIS
    • 19.21.3 PRODUCT PORTFOLIO
    • 19.21.4 RECENT DEVELOPMENTS
  • 19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 19.22.1 COMPANY SNAPSHOT
    • 19.22.2 REVENUE ANALYSIS
    • 19.22.3 PRODUCT PORTFOLIO
    • 19.22.4 RECENT DEVELOPMENTS
  • 19.23 TRUEDELL MEDICAL INTERNATIONAL
    • 19.23.1 COMPANY SNAPSHOT
    • 19.23.2 PRODUCT PORTFOLIO
    • 19.23.3 RECENT DEVELOPMENTS
  • 19.24 VIATRIS INC.
    • 19.24.1 COMPANY SNAPSHOT
    • 19.24.2 PRODUCT PORTFOLIO
    • 19.24.3 RECENT DEVELOPMENTS
  • 19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
    • 19.25.1 COMPANY SNAPSHOT
    • 19.25.2 REVENUE ANALYSIS
    • 19.25.3 PRODUCT PORTFOLIO
    • 19.25.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION 48
  • FIGURE 2 ASIA PACIFIC BRONCHIECTASIS MARKET : DATA TRIANGULATION 51
  • FIGURE 3 ASIA PACIFIC BRONCHIECTASIS MARKET: DROC ANALYSIS 52
  • FIGURE 4 ASIA PACIFIC BRONCHIECTASIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 53
  • FIGURE 5 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS 53
  • FIGURE 6 ASIA PACIFIC BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING 54
  • FIGURE 7 ASIA PACIFIC BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS 55
  • FIGURE 8 ASIA PACIFIC BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID 56
  • FIGURE 9 ASIA PACIFIC BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS 57
  • FIGURE 10 ASIA PACIFIC BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID 58
  • FIGURE 11 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION 62
  • FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE ASIA PACIFIC BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 63
  • FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BRONCHIECTASIS MARKET IN 2021 & 2028 63
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC BRONCHIECTASIS MARKET 73
  • FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050 75
  • FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019) 75
  • FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS 81
  • FIGURE 18 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021 89
  • FIGURE 19 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION) 90
  • FIGURE 20 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028) 90
  • FIGURE 21 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE 91
  • FIGURE 22 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2021 95
  • FIGURE 23 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION) 96
  • FIGURE 24 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028) 96
  • FIGURE 25 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE 97
  • FIGURE 26 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2021 101
  • FIGURE 27 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION) 102
  • FIGURE 28 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028) 102
  • FIGURE 29 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE 103
  • FIGURE 30 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021 117
  • FIGURE 31 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION) 118
  • FIGURE 32 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028) 118
  • FIGURE 33 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE 119
  • FIGURE 34 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 123
  • FIGURE 35 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 124
  • FIGURE 36 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028) 124
  • FIGURE 37 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 125
  • FIGURE 38 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2021 131
  • FIGURE 39 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION) 132
  • FIGURE 40 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028) 132
  • FIGURE 41 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE 133
  • FIGURE 42 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021 138
  • FIGURE 43 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 139
  • FIGURE 44 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 139
  • FIGURE 45 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 140
  • FIGURE 46 ASIA PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020) 145
  • FIGURE 47 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020) 147
  • FIGURE 48 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 147
  • FIGURE 49 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 148
  • FIGURE 50 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 148
  • FIGURE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020) 150
  • FIGURE 52 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020) 152
  • FIGURE 53 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 152
  • FIGURE 54 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 153
  • FIGURE 55 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 153
  • FIGURE 56 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 239
Back to Top